Physiological Features of Hemostasis in Newborn Calves Receiving Ferroglukin, Fosprenil and Hamavit, for Iron Deficiency

Newborn calves still often suffer from iron deficiency. This state damages their growth and development - to some extent, due to the development of pathological changes in hemostasis. Thereby, both veterinary science and cattle physiology give great scientific and practical significance to the search of approaches to effective correction of new-born calves’ hemostasis pathology connected with iron deficiency. It seemed to be perspective to evaluate the influence degree of ferroglukin, traditionally applied at iron deficiency, in combination with metabolism stimulators (fosprenil and hamavit) on new-born calves’ indices of hemostasis system. During our study it was established that new-born calves with iron deficiency were also characterized by decreased plasma antioxidant protect-ability, intensity of lipids’ peroxidation processes, increase of platelets’ hemostatic activity and blood coagulation system along with the decrease of vascular wall’s ability to bind it. In our study we found that combination of ferroglukin, fosprenil and hamavit given to new-born calves with iron deficiency showed improved plasma antioxidant and lipid peroxidation activity. Normalization of platelet activity, positive dynamics of hemostasis vascular and plasma components were also observed. Iron deficiency of new-born calves can be considered as the model of hemostasis abnormality. With its help we could try different means and their combinations to cure the pathology of hemostasis. The obtained results allowed us to consider the usage of fosprenil and hamavit combination on the background of ferroglukin to be sufficient for reducing the pathology of hemostasis in newborn calves with iron deficiency

Impact of Experimental Development of Arterial Hypertension and Dyslipidemia on Intravascular Activity of Rats' Platelets

Great interest is shown by researchers to functional and rheological features of basic regular blood elements. Platelets are among them and take the most active part in hemostasis at rather wide-spread nowadays cardio-vascular and metabolic diseases. The aim is to analyze dynamics’ strengthening of platelets' intravascular activity of rats in conditions of experimental consequent development of arterial hypertension and dyslipidemia. The study used 68 male-rats of Vistar line at the age of 2.5-3 months. Control group was composed of 33 animals. Experimental animals (35 rats) were developed at first – arterial hypertension (usage of cardioangiol pathogenic diet for 2 weeks and impact of cold at the end) and then - dyslipidemia (application of rich in calories diet at lowering of motor activity). The rats from experimental group were examined 5 times during the research. The rats from control group were examined twice - at the beginning and at the end of the experiment. While examining experimental and control rats we applied biochemical, hematological and statistical methods of investigation. At consequent arterial hypertension and dyslipidemia development experimental rats had gradual strengthening of lipids' peroxidation processes in plasma (acylhydroperoxides increased in 2.1 times) and platelets (acyl hydroperoxides increased in 1.4 times). Already at arterial hypertension development rats' blood was noted to have lowering of discocytes' quantity on 5.9%, deepening during the further dyslipidemia development on 7.4% more, and reaching 24.6±0.13%. This process was accompanied by gradual increase of activated platelets' sum on 75.7% during the whole period of investigation. The number of small, middle and large platelet aggregates, freely circulating in blood during modeling of double pathology, gradually increased in 2.8 times and in 10.3 times, respectively. Control rats had stable normal level of relevant biochemical and hematological characteristics. Subsequent development of at first arterial hypertension and then – dyslipidemia in rats gradually weakened their antioxidant protection of blood plasma and platelets and strengthened POL processes in them. It also strengthened lipids' peroxidation in them. Developing abnormalities gradually strengthened intravascular platelets' activity and their aggregative ability in experimental animals. The created model allowed tracking the earliest symptoms of strengthening of platelets’ intravascular activity against the background of AH and dyslipidemia development

Optimization of the functional state of the cardiovascular system in women with a complex of dosage physical exertion

In the second mature age, women increase the prevalence of arterial hypertension, often complicating hypertensive crises. This circumstance requires improving the recovery options for this category of patients. It seems very promising to be used for this in women with arterial hypertension regular physical exertion for the purpose of their overall recovery, reducing the level of blood pressure and the prevention of hypertensive crise

Physiological features of the cardiovascular system in hypertensive men under conditions of regular physical activity

In modern society, men often have arterial hypertension at the beginning of adulthood, which can progress rapidly and be complicated by thrombosis. It becomes necessary to improve the process of physical rehabilitation of hypertensive men of mature age. For this purpose, in men diagnosed with arterial hypertension, various schemes of systematic muscle activity are use

Оценка экспрессии PD-L1 у пациентов с уротелиальным раком, имеющих противопоказания к назначению препаратов платины

Background. Urothelial cancer ranks 7th and 17th of all the malignant tumors in males and females, respectively. Development of new immunotherapeutic drugs provides new possibilities in treatment of such patients, especially the patient population in whom platinum‑based therapy is contraindicated. Administration of immunooncology drugs requires determination of PD-L1, for which various diagnostic systems are used. The question regarding correlation of results of determination of PD-L1 expression remains of concern.Materials and Methods. The study was performed on 100 samples of surgical and biopsy samples of urothelial cancer. Two clones of 22C3 and SP142 with corresponding detection systems were used for the study. PD-L1 expression was assessed in tumor and immune cells.Results. The study demonstrated a high correlation of negative PD-L1 tumor status determined using both diagnostic agents (92 % and 97 %) and low correlation of results of positive PD-L1 status (67 % and 43 %).Conclusions. Thus, if a negative result of PD-L1 status of urothelial cancer is obtained using any of the diagnostic agents studied, repeated test with the other antibody is not required. If positive status is obtained in one test, the patient may have a negative status in the other test, which allows recommending a repeated testing in borderline cases using a test, recommended for the medicinal product untended for treatment.Уротелиальный рак мочевого пузыря во всем мире находится на 7 и Введение. Уротелиальный рак во всем мире находится на 7 и 17 местах среди всех злокачественных опухолей у мужчин и женщин соответственно. Появление новых иммунотерапевтических препаратов открывает новые возможности для лечения таких пациентов, особенно учитывая группу пациентов, имеющих противопоказания к назначению препаратов платины. Применение иммуноонкологических препаратов требует определения экспрессии PD-L1, для которого используются различные диагностические системы. Актуальным является вопрос о сопоставлении результатов определения экспрессии PD-L1 разными методами.Материалы и методы. Исследования проведено на 100 образцах операционного и биопсийного материала уротелиального рака. Для исследования были использованы два клона антител 22C3 и SP142 с соответствующими системами детекции. Оценивалась экспрессия PD-L1 в опухолевых и иммунных клетках.Результаты. Исследование показало высокое совпадение негативного PD-L1 статуса опухоли, выявленного при использовании обоих диагностикумов (92% и 97%) и низкое совпадение результатов по позитивному PD-L1 статусу (67% и 43%).Выводы. Таким образом, при получении негативного результата PD-L1 статуса уротелиального рака любым из исследованных диагностикумов не требуется повторное тестирование с другим антителом. При обнаружении позитивного статуса по одному тесту пациент может иметь негативный статус по другому тесту, что позволяет рекомендовать повторное тестирование в пограничных случаях с тестом, рекомендованным для предполагаемого для лечения препарата

Сравнение иммуногистохимических тестов в рамках исследования CLOVER Российского общества клинической онкологии

Introduction. The goal of the CLOVER study performed by the Russian Society of Clinical Oncology, was a pairwise comparison of three validated PD-L1 immunohistochemical (IHC) tests (Ventana SP142, Ventana SP263, Dako 22C3) in the patient population with non-small cell lung cancer (NSCLC). This study is the first large Russian comparative study to evaluate PD-L1 expression levels using immunohistochemistry methods.Materials and methods. The study was conducted on 473 NSCLC samples from Biobank. The IHC tests were carried out with 3 antibody clones. Four trained pathologists independently evaluated the percentage of positively stained tumor cells (TC) and immune cells (IC). To assess the correlation of TC and IC between different runs and the prognostic values of one test for another, a concordant analysis was used.Results. The number of PD-L1‑positive cells (≥1 %) was higher among IC compared with TC in all three IHC tests. Pearson correlation coefficients (PCC) for TCs were 0.71, 0.87, and 0.75 for 22C3 / SP142, 22C3 / SP263 and SP263 / SP142, respectively. PCC values for ICs were 0.45, 0.61, and 0.68 for the same pairs. A high coincidence of positive and negative results (>91 %) was obtained between the staining with antibodies 22C3 and SP263 of immunooncological agents in the 1st line.Conclusions. The highest correlation between IHC tests was obtained by pairwise comparison of 22C3 and SP263. Clone 22C3 can be considered as a substitute for SP263 in the first-line treatment of NSCLC. Clone SP142 showed weaker expression in TC and IC compared to the other two tests in patients with non-small cell lung cancer.Введение. Целью исследования CLOVER, проведенного Российским обществом клинической онкологии, было попарное сравнение трех валидированныхиммуногистохимических (ИГХ) тестов PD-L1 (Ventana SP142, Ventana SP263, Dako 22C3) на одной и той же популяции пациентов с немелкоклеточным раком легкого (НМРЛ). Данное исследование — это первое крупное росийское сравнительное исследование по оценке определения уровней экспрессии PD-L1 методами иммуногистохимии.Материалы и методы. Работа проведена на 473 образцах НМРЛ, полученных из Биобанка. Иммуногистохимическое исследование проведено с использованием 3 клонов антител. Четыре подготовленных патологоанатома независимо оценивали процентное содержание положительно окрашенных опухолевых клеток (ОК) и иммунных клеток (ИК). Для оценки корреляции ОК и ИК между различными анализами и прогностических свойств одного теста для другого был проведен конкордантный анализ.Результаты. Число PD-L1-позитивных клеток (1% и более) было выше среди ИК по сравнению с ОК во всех трех иммуногистохимических исследованиях. Коэффициенты корреляции Пирсона (PCC) для ОК составили 0,71, 0,87 и 0,75 между 22C3/SP142, 22C3/SP263 и SP263/SP142 соответственно. Значения PCC для ИК составили 0,45, 0,61 и 0,68 для тех же пар. Было получено высокое совпадение положительных и отрицательных результатов (>91%) между окрашиванием, полученным с антителами 22C3 и SP263 для иммуноонкологических препаратов в 1 линии.Выводы. Наиболее высокая корреляция ИГХ анализов была получена при попарном сравнении 22C3 и SP263. Клон 22C3 можно рассматривать в качестве замены SP263 при лечении НМРЛ в первой линии. Клон SP142 показал более слабую экспрессию в ОК и ИК по сравнению с двумя другими анализами у пациентов с плоскоклеточным раком

COMPARISON OF OPPORTUNITIES FROM TWO THERAPEUTICAL COMPLEXES FOR CORRECTION OF VASCULAR HEMOSTASIS IN HYPERTENSIVES WITH METABOLIC SYNDROME

Though there is a progress in medical science and practice, hypertension remains widely prevalent in economically developed countries, and is comorbid with metabolic syndrome. This leads to weakening of vascular wall functioning in these patients and developing conditions for the formation of intravascular thrombi of various location.Aim. Comparative assessment of hemostatic function correction of vessel wall in hypertensives with metabolic syndrome (MS) with the complex of valsartan and losartan together with metformin and nonmedication treatments.Material and methods. Under follow-up, there were 47 hypertensives, of 1-2 grade, risk 4, middle age. Controls were 25 healthy persons of the same age. The assessment of biochemical and hematological parameters was performed. For blood pressure correction, 24 patients were prescribed valsartan 160 mg daily, 23 patients — losartan 100 mg daily. For metabolism optimization all patients were prescribed metformin 500 mg b.i.d., hypocaloric diet and regular physical activity of tolerable intensity.Results. The application of a complex with valsartan leads to normalization in hypertensives with MS the function of vascular wall in 4 months. Further non-strict adherence to the prescribed nonmedication part of the complex retains positive effect by the end of follow-up (12 months). Usage of losartan improves, but does not normalize vessel wall function in 4 months. Further non-strict adherence of non-medication part of treatment, regardless the continuation of losartan and metformin intake, decreases the achieved effect of treatment.Conclusion. Usage of treatment complex of hypocaloric diet, physical exercise and metformin helps to influence positively vascular hemostasis in hypertensives with MS in case of valsartan inclusion, and is less effective if replaced by losartan